Andrew James King, Chief Scientific Officer at CHINOOK THERAPEUTICS, INC. (KDNY), sold 2,500 shares at $13.00 ($33K) on 2022-02-18, disclosed to the SEC on 2022-02-23.
Scheduled sale ($32k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KDNY | SELL | 2023-02-15 | $57K | — | Filing → |
| KDNY | SELL | 2023-02-02 | $160K | — | Filing → |
| KDNY | SELL | 2023-01-04 | $258K | — | Filing → |